Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

Summary

This study will examine the effect of a single high dose of psilocybin therapy (30 mg) versus a very low dose (1 mg) as an adjunctive therapy to individuals undergoing standard-of-care buprenorphine treatment for Opioid use disorder (OUD). Effects of adjunctive psilocybin will be determined for longitudinal outcomes of opioid abstinence, compliance with buprenorphine maintenance, quality of life, and mood.

Timeline

Start

2027-04

Primary completion

2028-07

Completion

2028-07

Outcome

Outcome not reported

Stopped: “This study was de-prioritized in favor of the similar BIPOD-Out protocol due to a combination of practical considerations and expense. There are currently no plans to initiate this protocol.”

Drugs

Indications